000125616 001__ 125616
000125616 005__ 20240228143319.0
000125616 0247_ $$2doi$$a10.1200/JCO.2015.66.0001
000125616 0247_ $$2pmid$$apmid:27432915
000125616 0247_ $$2pmc$$apmc:PMC5505170
000125616 0247_ $$2ISSN$$a0732-183X
000125616 0247_ $$2ISSN$$a1527-7755
000125616 0247_ $$2altmetric$$aaltmetric:9844322
000125616 037__ $$aDKFZ-2017-01742
000125616 041__ $$aeng
000125616 082__ $$a050
000125616 1001_ $$aChagtai, Tasnim$$b0
000125616 245__ $$aGain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
000125616 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2016
000125616 3367_ $$2DRIVER$$aarticle
000125616 3367_ $$2DataCite$$aOutput Types/Journal article
000125616 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521723162_2108
000125616 3367_ $$2BibTeX$$aARTICLE
000125616 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125616 3367_ $$00$$2EndNote$$aJournal Article
000125616 520__ $$aWilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under International Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many relapses occur in patients without specific risk factors, and many successfully treated patients are exposed to treatments with significant risks of late effects. To investigate whether molecular biomarkers could improve risk stratification, we assessed 1q status and other potential copy number biomarkers in a large WT series.WT nephrectomy samples from 586 SIOP WT 2001 patients were analyzed using a multiplex ligation-dependent probe amplification (MLPA) assay that measured the copy number of 1q and other regions of interest.One hundred sixty-seven (28%) of 586 WTs had 1q gain. Five-year event-free survival (EFS) was 75.0% in patients with 1q gain (95% CI, 68.5% to 82.0%) and 88.2% in patients without gain (95% CI, 85.0% to 91.4%). OS was 88.4% with gain (95% CI, 83.5% to 93.6%) and 94.4% without gain (95% CI, 92.1% to 96.7%). In univariable analysis, 1q gain was associated with poorer EFS (P < .001; hazard ratio, 2.33) and OS (P = .01; hazard ratio, 2.16). The association of 1q gain with poorer EFS retained significance in multivariable analysis adjusted for 1p and 16q loss, sex, stage, age, and histologic risk group. Gain of 1q remained associated with poorer EFS in tumor subsets limited to either intermediate-risk localized disease or nonanaplastic localized disease. Other notable aberrations associated with poorer EFS included MYCN gain and TP53 loss.Gain of 1q is a potentially valuable prognostic biomarker in WT, in addition to histologic response to preoperative chemotherapy and tumor stage.
000125616 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000125616 588__ $$aDataset connected to CrossRef, PubMed,
000125616 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000125616 7001_ $$aZill, Christina$$b1
000125616 7001_ $$aDainese, Linda$$b2
000125616 7001_ $$aWegert, Jenny$$b3
000125616 7001_ $$aSavola, Suvi$$b4
000125616 7001_ $$aPopov, Sergey$$b5
000125616 7001_ $$aMifsud, William$$b6
000125616 7001_ $$aVujanić, Gordan$$b7
000125616 7001_ $$aSebire, Neil$$b8
000125616 7001_ $$aLe Bouc, Yves$$b9
000125616 7001_ $$aAmbros, Peter F$$b10
000125616 7001_ $$aKager, Leo$$b11
000125616 7001_ $$aO'Sullivan, Maureen J$$b12
000125616 7001_ $$aBlaise, Annick$$b13
000125616 7001_ $$aBergeron, Christophe$$b14
000125616 7001_ $$aMengelbier, Linda Holmquist$$b15
000125616 7001_ $$aGisselsson, David$$b16
000125616 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b17$$udkfz
000125616 7001_ $$aTytgat, Godelieve A M$$b18
000125616 7001_ $$avan den Heuvel-Eibrink, Marry M$$b19
000125616 7001_ $$aGraf, Norbert$$b20
000125616 7001_ $$avan Tinteren, Harm$$b21
000125616 7001_ $$aCoulomb, Aurore$$b22
000125616 7001_ $$aGessler, Manfred$$b23
000125616 7001_ $$aWilliams, Richard Dafydd$$b24
000125616 7001_ $$aPritchard-Jones, Kathy$$b25
000125616 773__ $$0PERI:(DE-600)2005181-5$$a10.1200/JCO.2015.66.0001$$gVol. 34, no. 26, p. 3195 - 3203$$n26$$p3195 - 3203$$tJournal of clinical oncology$$v34$$x1527-7755$$y2016
000125616 909CO $$ooai:inrepo02.dkfz.de:125616$$pVDB
000125616 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000125616 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000125616 9141_ $$y2016
000125616 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000125616 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ONCOL : 2015
000125616 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125616 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125616 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125616 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125616 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125616 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125616 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125616 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125616 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125616 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bJ CLIN ONCOL : 2015
000125616 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000125616 980__ $$ajournal
000125616 980__ $$aVDB
000125616 980__ $$aI:(DE-He78)B062-20160331
000125616 980__ $$aUNRESTRICTED